Recent events
Recent events tied to this brand in public sources.
Back to profile5 entries
2021
Moderna and AbCellera launch antibody-development collaboration
Moderna and AbCellera announced a collaboration to develop mRNA-encoded antibody drugs, combining Moderna’s mRNA platform with AbCellera’s antibody discovery platform. AbCellera’s platform will identify antibodies against up to six targets selected by Moderna.
2020
AbCellera acquires the OrthoMab platform
AbCellera acquired full rights to the OrthoMab bispecific platform from Dualogics under an asset purchase agreement.
2020
AbCellera files patent infringement lawsuit against Berkeley Lights
AbCellera filed a lawsuit against Berkeley Lights alleging infringement of eight U.S. patents and seeking declaratory relief, damages and a permanent injunction.
2020
EpiVax licenses ISPRI toolkit to AbCellera
EpiVax announced that it licensed its ISPRI in silico immunogenicity screening toolkit to AbCellera, which plans to use it in its antibody discovery programs.
2020
AbCellera and Lilly enter multi-year antibody discovery collaboration
AbCellera announced that it had entered a multi-year strategic research collaboration and license agreement with Eli Lilly and Company to discover antibodies for up to nine Lilly-selected therapeutic targets. Lilly will have rights to develop and commercialize resulting therapeutic products.